生命科学与工程系表观遗传学学术报告

应amjs澳金沙官网生命科学与工程系吴琼教授邀请，上海交通大学肿瘤研究所，癌基因及相关基因国家重点实验室，肿瘤表观遗传学和基因治疗组课题负责人朱景德教授于9月18日来amjs澳金沙官网访问讲学，欢迎广大师生参加。

 

报告题目：DNA methylation perspective of biological behaviors in the normal and diseases

报告人：朱景德教授

时间: 9月18日上午9点

地点：科学园2E栋405室

 

报告摘要：

Epigenetics concerns the signals and mechanisms for the cross-cell-generation transmission of the gene expression memory and is one of a few most rapidly developing entity in the life sciences today. DNA methylation is the best characterized and holds promise for a better diagnostics for personalized prevention, prediction and practice of medicine.  In addition to the overall and historical pictures (1/3 of the time required), we will use my own works as the paradigms, to highlight the translational aspects of our efforts (the remaining 2/3).   1, the whole solution to the DNA methylation diagnostics, the methylomic profiling/clinical validation/assay development tailored to clinical practice; 2, the multiplex qPCR based DNA methylation analysis kit for bladder cancer as a paradigm; 3, the technological refinements of ours to bring the cancer diagnostics into practice

The 1/3^rd

1, The epigenetic perspectives of biological behaviors:

2, The epigenetic perspectives of the diseases;

3, The concepts and approaches in the era of epigenome;

The remaining 2/3^rd

1, The epigenetic aspects of the cancer, the only disease of the aberrant cell proliferation;

2, The epigenetic challenges in the era of the personalized cancer medicine;

3, The approaches of ours;

1), the DNA methylomic studies of ours;

2), the technological advances;

3), DNA methylation diagnostics of ours;

 

主讲人简介：

Jingde Zhu

Cancer Epigenetics Program, Shanghai Cancer Institute/Renji Hospital,

Shanghai Jiaotong University, Shanghai 200032, China

 

Biography

Jingde Zhu, Ph.D (1985) in molecular pathology from Beatson Institute for Cancer Research, Glasgow, UK.  Then worked as a senior scientist or PI in Shanghai Institute of Cell Biology, three academic institutions and one biotech firm abroad between 1985-2001.  He has approached to the epigenetics(-omics) behaviors of cancer from both basic and translational perspectives. His research has been supported by the funds from the European 6^th frame as well as  from both local and central governments of China.  Jingde Zhu is the inventor for both approved and filed patents (six) in China and in US. As member of AACR Epigenome Task Force and of Asian Epigenome Alliance, he represents China in IHEC (The International Human Epigenome Consortium), and Asian Epigenome Alliance to actively promote the regional and global epigenomic studies. He has organized 6 international conferences since 2003 in Shanghai and presented his researches on over 120 occasions since 2002.  He acts as an editor in 5 SCI journals and reviewers for over ten journals.  He has published over 50 SCI paper since 2002.

 

5 recent representative publication (*, the principal author)

1*, Nat Biotechnol 28(5): 516-20(2010).

2*, Plos Biology, 2010, 8(11), e1000533

3*, Int J Biochem Cell Biol 41(1): 147-154(2009).

4, Nature 454(7205): 711-5(2008)

5*, Clin Cancer Res 13(24): 7296-304(2007).